175 related articles for article (PubMed ID: 22411419)
1. Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates.
Hamidi Madani A; Enshaei A; Heidarzadeh A; Mokhtari G; Farzan A; Mohiti Asli M; Esmaeili S
World J Urol; 2013 Feb; 31(1):235-9. PubMed ID: 22411419
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
[TBL] [Abstract][Full Text] [Related]
3. Outcome of Botulinum Toxin-A intraprostatic injection for benign prostatic hyperplasia induced lower urinary tract symptoms: A prospective multicenter study.
Moussa AS; Ragheb AM; Abdelbary AM; Ibrahim RM; El Adawy MS; Aref A; Assem A; Elfayoumy H; Elzawy F
Prostate; 2019 Aug; 79(11):1221-1225. PubMed ID: 31189024
[TBL] [Abstract][Full Text] [Related]
4. Intraprostatic botulinum toxin type "A" injection in patients with benign prostatic hyperplasia and unsatisfactory response to medical therapy: A randomized, double-blind, controlled trial using urodynamic evaluation.
Totaro A; Pinto F; Pugliese D; Vittori M; Racioppi M; Foschi N; Bassi PF; Sacco E
Neurourol Urodyn; 2018 Mar; 37(3):1031-1038. PubMed ID: 28840969
[TBL] [Abstract][Full Text] [Related]
5. Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia.
de Kort LM; Kok ET; Jonges TN; Rosier PF; Bosch JL
Urology; 2012 Oct; 80(4):889-93. PubMed ID: 22854138
[TBL] [Abstract][Full Text] [Related]
6. Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a randomized clinical trial.
Robert G; Descazeaud A; Karsenty G; Saussine C; Azzouzi AR; de la Taille A; Desgrandchamps F; Faix A; Fourmarier M; Georget A; Benard A; Barry Delongchamps N
World J Urol; 2018 Jun; 36(6):921-929. PubMed ID: 29383480
[TBL] [Abstract][Full Text] [Related]
7. Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia: a comparative study of medium- and large-volume prostates.
Wang M; Guo L; Duan F; Yuan K; Zhang G; Li K; Yan J; Wang Y; Kang H
BJU Int; 2016 Jan; 117(1):155-64. PubMed ID: 25851432
[TBL] [Abstract][Full Text] [Related]
8. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia.
Chuang YC; Chiang PH; Yoshimura N; De Miguel F; Chancellor MB
BJU Int; 2006 Nov; 98(5):1033-7; discussion 1337. PubMed ID: 16956361
[TBL] [Abstract][Full Text] [Related]
9. Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption.
Silva J; Silva C; Saraiva L; Silva A; Pinto R; Dinis P; Cruz F
Eur Urol; 2008 Jan; 53(1):153-9. PubMed ID: 17825981
[TBL] [Abstract][Full Text] [Related]
10. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
Jhang JF; Jiang YH; Kuo HC
Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
[TBL] [Abstract][Full Text] [Related]
11. Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation?
Chiang BJ; Kuo HC; Liao CH
Toxins (Basel); 2019 Sep; 11(9):. PubMed ID: 31546892
[TBL] [Abstract][Full Text] [Related]
12. Prostate artery embolization has long term efficacy for treatment of severe lower urinary tract symptoms from giant prostatic hyperplasia.
Somwaru AS; Metting S; Flisnik LM; Nellamattathil MG; Sharma A; Katabathina VS
BMC Urol; 2020 Oct; 20(1):153. PubMed ID: 33032577
[TBL] [Abstract][Full Text] [Related]
13. Transperineal intraprostatic injection of botulinum neurotoxin A vs transurethral resection of prostate for management of lower urinary tract symptoms secondary to benign prostate hyperplasia: A prospective randomised study.
El-Dakhakhny AS; Gharib T; Issam A; El-Karamany TM
Arab J Urol; 2019; 17(4):270-278. PubMed ID: 31723444
[No Abstract] [Full Text] [Related]
14. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.
Marberger M; Chartier-Kastler E; Egerdie B; Lee KS; Grosse J; Bugarin D; Zhou J; Patel A; Haag-Molkenteller C
Eur Urol; 2013 Mar; 63(3):496-503. PubMed ID: 23098762
[TBL] [Abstract][Full Text] [Related]
15. Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment.
Silva J; Pinto R; Carvalho T; Botelho F; Silva P; Oliveira R; Silva C; Cruz F; Dinis P
BMC Urol; 2009 Aug; 9():9. PubMed ID: 19682392
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin A injection to the bladder neck and urethra for medically refractory lower urinary tract symptoms in men without prostatic obstruction.
Chen JL; Chen CY; Kuo HC
J Formos Med Assoc; 2009 Dec; 108(12):950-6. PubMed ID: 20040460
[TBL] [Abstract][Full Text] [Related]
17. Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses.
Arnouk R; Suzuki Bellucci CH; Benatuil Stull R; de Bessa J; Malave CA; Mendes Gomes C
ScientificWorldJournal; 2012; 2012():463574. PubMed ID: 22997495
[TBL] [Abstract][Full Text] [Related]
18. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
19. Intraprostatic botulinum neurotoxin type a injection for benign prostatic hyperplasia: preliminary results with a newly purified neurotoxin.
Yokoyama T; Yamamoto Y; Suzuki T; Oguma K; Nagai A
Acta Med Okayama; 2012; 66(4):291-7. PubMed ID: 22918201
[TBL] [Abstract][Full Text] [Related]
20. Intraprostatic injection of alcohol gel for the treatment of benign prostatic hyperplasia: preliminary clinical results.
Larson BT; Netto N; Huidobro C; de Lima ML; Matheus W; Acevedo C; Larson TR
ScientificWorldJournal; 2006 Sep; 6():2474-80. PubMed ID: 17619720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
